Application of transient receptor potential cation channel TRPV3 in developing drug for preventing or treating psoriasis

A method for screening a drug for treating a transient receptor potential cation channel (TRPV3)-related psoriasis comprising the following steps:

• culturing a cell line expressing the TRPV3, adding Fluo-4, adding a test drug and 2-aminoethoxybiphenylborate (2-APB), recording a fluorescence signal at a wavelength between 515 nm and 575 nm as a basic fluorescence signal when excited at a wavelength of 488 nm, adding the 2-APB, recording the fluorescence signal as a response fluorescence signal, the test drug is a candidate drug for treating the transient receptor potential cation channel (TRPV3)-related psoriasis when a value of the response fluorescence signal is bigger than that of the basic fluorescence signal.